Latest Presentation
Recent Event
Full Fiscal Year 2022 Earnings and Business Update Conference Call
Latest Financial Results
FY 2022
Fiscal Year Ended Dec 31, 2022
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2022
Report Links
Email Alerts
Sign up today and receive company updates straight to your inbox.
Company Overview
Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Volition's research and development activities are centered in Belgium, with an innovation hub in California and additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic and disease monitoring products to market.